Coagulation: connect assays to bleeding and thrombosis
Connect coagulation complexes, PT and aPTT, mixing studies and bleeding patterns to factor disorders, inhibitors, consumption and drug reversal.
A prolonged clotting time is an observation about a laboratory reaction. It is not automatically a prediction of bleeding. Interpret the assay alongside the patient's bleeding or thrombosis, medications and factor biology before deciding whether to replace a factor, investigate an inhibitor or reverse a drug.
Build thrombin on a surface, then stabilize fibrin
At an injured vessel, tissue factor interacts with factor VIIa to initiate activation of factors IX and X. Activated platelets provide a phospholipid surface on which enzyme-cofactor complexes work efficiently in the presence of calcium. IXa with VIIIa forms intrinsic tenase, which activates X. Xa with Va forms prothrombinase, which converts factor II, prothrombin, into thrombin. Factors V and VIII are cofactors, so the common pathway is not a literal serial sequence of X turning into V and then II.
Enzyme and cofactor partners converge on thrombin
Initiation
Tissue factor + VIIa → activation of IX and X.
Amplification on activated platelets
IXa + VIIIa + calcium/phospholipid → more Xa. Xa + Va + calcium/phospholipid → thrombin.
Clot formation and stabilization
Thrombin converts fibrinogen to fibrin and activates XIII. XIIIa crosslinks fibrin to strengthen the clot.
Each plus sign means cooperating components, not one factor becoming another. Thrombin also activates platelets through PAR-1 and PAR-4 and activates factors V, VIII and XI, amplifying its own generation. [3]
Thrombin has regulatory functions as well as clot-promoting ones. When bound to endothelial thrombomodulin, it activates protein C. Activated protein C, assisted by protein S, inactivates Va and VIIIa. Antithrombin restrains thrombin and Xa; heparin enhances antithrombin's inhibitory activity. Factor V Leiden is resistance to activated protein C, a thrombotic tendency, and is distinct from factor V deficiency, a bleeding disorder. Severe congenital protein C deficiency can cause neonatal purpura fulminans.
The fibrinolytic system limits the clot: tissue plasminogen activator helps generate plasmin, which digests fibrin. D-dimer arises from degradation of crosslinked fibrin and signals fibrin turnover, not one specific diagnosis. Tranexamic acid inhibits fibrinolysis and can help selected mucosal or surgical bleeding, but it does not replace a missing coagulation factor or reverse every anticoagulant. [5][9]
Try it here · Checkpoint 1 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 30
Show answer and explanations for case 30
A. Factor VIII activity (Why this does not fit)
Severe VIII deficiency usually prolongs aPTT; the delayed stump bleeding with normal screening times makes XIII particularly relevant.
B. Factor XII activity (Why this does not fit)
XII deficiency prolongs aPTT but generally does not cause a bleeding phenotype.
C. Factor XIII activity (Best answer)
XIII stabilizes fibrin after the endpoint measured by PT and aPTT, so deficiency can escape both screens.
D. Factor VII activity (Why this does not fit)
Significant VII deficiency usually prolongs PT, unlike the normal PT here.
Takeaway: Normal initial clot formation does not prove normal clot stabilization.
Read PT and aPTT as different laboratory entry points
PT assesses the tissue-factor entry pathway and common pathway, making it sensitive to factor VII and to factors X, V, II and fibrinogen. aPTT starts through contact activation and assesses XII, XI, IX and VIII plus common-pathway function. Factor XII is important to this test reaction, yet its deficiency generally does not cause a bleeding phenotype. In-vivo initiation and the laboratory contact pathway are therefore not interchangeable descriptions. [1]
Screening patterns guide the next investigation
PT
aPTT
Useful possibilities
PTProlonged
aPTTNormal
Useful possibilitiesFactor VII deficiency; early vitamin K deficiency or VKA effect; selected drug or liver effects.
PTNormal
aPTTProlonged
Useful possibilitiesVIII, IX or XI deficiency; XII/contact-factor deficiency; heparin; lupus anticoagulant; specific inhibitor.
PTProlonged
aPTTProlonged
Useful possibilitiesCommon-factor or multiple deficiencies, advanced consumption, liver disease or anticoagulant effects.
PTNormal
aPTTNormal
Useful possibilitiesVWD, platelet dysfunction, mild factor deficiency, XIII deficiency or some anticoagulant exposures remain possible.
PT and aPTT stop when an initial fibrin clot is detected. They do not directly assess its later XIII-dependent crosslinking. Delayed umbilical bleeding or recurrent delayed bleeding despite normal screening times warrants specific evaluation rather than reassurance. Mild hemophilia may also escape an insensitive screening reagent. Bleeding time is obsolete as a routine diagnostic test for platelet or VWF disorders. [1][16][17]
INR standardizes PT principally for vitamin K antagonist monitoring. It does not measure the full balance of procoagulant and anticoagulant proteins in cirrhosis, and does not provide a stand-alone prediction of procedural bleeding. Do not transfuse plasma merely to achieve a normal INR in an otherwise stable cirrhotic patient. Assess the procedure, portal hypertension, bleeding, fibrinogen, platelets and overall condition. [13]
Mixing asks whether normal plasma can supply what is missing
Before interpreting a mixing study, review anticoagulants and sample quality. A heparinized-line draw can prolong aPTT. Direct oral anticoagulants can distort screening times, factor assays and lupus-anticoagulant testing. Drug-aware testing or a clean peripheral sample may resolve an apparent inhibitor pattern.
A 1:1 mix is a controlled replacement experiment
Correction persists
Patient plasma + normal pooled plasma → adequate missing-factor supply → consider factor deficiency, then identify the factor.
Correction fails or is lost with incubation
An inhibitor or interfering drug still acts in the mixture → investigate the specific cause. Some VIII inhibitors reveal their effect only after incubation.
The laboratory defines correction using its validated method. A mixture is evidence about a mechanism, not the final diagnosis. Pure XII deficiency can correct normally; it is not defined by delayed loss of correction. [2]
An older adult or postpartum patient with new extensive soft-tissue bleeding, isolated prolonged aPTT and a time-dependent VIII inhibitor may have acquired hemophilia A. Obtain factor activity and inhibitor testing promptly and involve a specialist for bleeding control and inhibitor eradication. This differs from lifelong congenital hemophilia with familial hemarthroses. [18]
Lupus anticoagulants interfere with phospholipid-dependent assays and may prolong aPTT without causing the expected bleeding phenotype. Clinical concern is often thrombosis. Evaluation uses appropriately selected assays such as dilute Russell viper venom time with confirmation of phospholipid dependence. Antiphospholipid syndrome requires clinical context and persistent relevant antibodies; repeat testing at least 12 weeks apart helps distinguish persistence from transient positivity. A single positive result during infection or one unexplained early miscarriage does not settle the diagnosis. Research classification criteria support standardized cohorts and should not be treated as an automatic bedside diagnostic calculator. [6]
Try it here · Checkpoint 2 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 3
Show answer and explanations for case 3
A. Factor VII deficiency (Why this does not fit)
VII deficiency primarily prolongs PT, which is normal here.
B. Factor XI deficiency (Best answer)
The factor assay and procedure-associated bleeding identify XI deficiency.
C. Factor XII deficiency (Why this does not fit)
XII activity is normal and its deficiency usually lacks this bleeding phenotype.
D. Lupus anticoagulant as the established cause (Why this does not fit)
A correcting mix and isolated XI reduction favor deficiency rather than the proposed inhibitor.
Takeaway: Use factor testing and the bleeding context to resolve an isolated aPTT abnormality.
Match the bleeding pattern to the missing function
Hemophilia A reduces factor VIII; hemophilia B reduces IX. Deep muscle bleeding and hemarthroses are characteristic, while platelet number and PT are usually normal. Severe disease generally has factor activity below 1%, moderate disease 1% to 5%, and mild disease above 5% and below 40%. X-linked inheritance means males are often affected, but females can have clinically significant low factor activity through several genetic mechanisms, including skewed X inactivation. Family history may be absent.
Factor assays distinguish A from B; desmopressin nonresponse does not. Desmopressin can release endogenous VWF and VIII and help responsive mild hemophilia A after testing. It does not supply IX in hemophilia B. Factor replacement and prophylaxis are individualized. Emicizumab provides VIII-like cofactor function by bringing IXa and X together in hemophilia A; it is not factor VIII itself. It markedly affects aPTT-based assays, so a short aPTT cannot be interpreted as a normal native VIII level. Bovine-reagent chromogenic assays can assess VIII activity and inhibitors in its presence. [3][15]
VWF connects platelet adhesion with coagulation by binding the platelet GPIb-IX-V receptor at an injured vessel and stabilizing circulating VIII. VWD therefore commonly produces nosebleeds, heavy menstrual bleeding and dental bleeding, while aPTT may be normal or prolonged depending on VIII. Test VWF antigen, platelet-dependent activity and VIII activity, ideally when the patient is at baseline health because stress, pregnancy and inflammation can increase VWF. Modern GPIb-based activity methods are preferred over older ristocetin-cofactor methods when available. [4]
VWD subtypes change interpretation and treatment
Type
Defect
Practical consequence
Type1
DefectPartial quantitative deficiency
Practical consequenceSome patients respond to desmopressin; establish response when indicated.
Type2A / 2M
DefectQualitative platelet interaction defects; large multimers reduced in 2A but relatively preserved in 2M
Practical consequenceLow activity can be disproportionate to antigen.
Type2B
DefectExcess binding to platelet GPIb
Practical consequenceThrombocytopenia can occur; desmopressin can worsen it.
Type2N
DefectPoor VIII binding
Practical consequenceLow VIII can resemble hemophilia A; inheritance and specialized testing distinguish them.
Type3
DefectNear absence of VWF
Practical consequenceSevere bleeding and low VIII; desmopressin lacks useful stores to release.
Distinguish platelet receptor disorders from VWD: Bernard-Soulier disease affects GPIb-IX-V, often with giant low-count platelets and impaired ristocetin agglutination. Glanzmann disease affects GPIIb/IIIa-mediated fibrinogen bridging, usually with normal platelet number and preserved ristocetin agglutination. These are distinct failures of adhesion and aggregation even when both cause mucosal bleeding. [17]
Tranexamic acid can assist selected mucosal bleeding. VWF concentrate is used when adequate factor support is required and desmopressin is ineffective or inappropriate. Avoid desmopressin in type 2B and do not use it as sole therapy for major surgery. Its water-retaining effect can cause hyponatremia, so fluid planning matters. FFP and cryoprecipitate are not the routine preferred replacement strategy when suitable VWF products are available. [5]
When clotting and bleeding coexist, identify the trigger or drug
DIC is systemic activation of coagulation with consumption of platelets and factors. Sepsis, major trauma, obstetric emergencies and acute promyelocytic leukemia are important triggers. Falling platelets, increasing PT, increased fibrin breakdown and falling fibrinogen support the diagnosis, but early DIC can have a normal fibrinogen because it is an acute-phase protein; aPTT may also be normal. Use serial clinical and laboratory assessment. Treat the trigger, and give blood components for clinically important bleeding or procedural needs rather than correcting every isolated laboratory value. Anticoagulation can be appropriate in selected thrombosis-predominant cases. [9]
TTP produces platelet-rich microvascular thrombosis associated with severe ADAMTS13 deficiency; PT/aPTT are often normal. Hemolysis with schistocytes and thrombocytopenia merits urgent evaluation without requiring a full pentad. Shiga-toxin HUS can follow bloody diarrhea with kidney injury and fragmentation; complement-mediated TMA requires a different evaluation. Do not collapse these disorders into TTP solely because schistocytes are present. [19] HIT is different: antibodies activate platelets through PF4-heparin complexes, causing thrombosis with a platelet fall.
Assess the 4Ts, especially a fall greater than 50% around days 5 to 10, thrombosis and competing causes. For intermediate or high 4Ts probability, stop all heparin and choose nonheparin anticoagulation while testing. High probability or a separate therapeutic indication usually warrants therapeutic intensity. With intermediate probability, high bleeding risk and no other therapeutic indication, ASH suggests prophylactic intensity while the initial testing proceeds.
Do not substitute LMWH. Delay warfarin until platelet recovery; platelet transfusion is not routine but can be necessary for active major bleeding. [8][7]
Vitamin K enables gamma-carboxylation of factors II, VII, IX and X and proteins C and S. Deficiency may follow malabsorption, poor intake or prolonged antibiotic exposure. VII's short half-life makes PT an early affected assay. Warfarin impairs vitamin K recycling; early protein C loss can contribute to skin necrosis, especially with underlying deficiency. Initial overlap with another anticoagulant is needed for acute VTE treatment, not automatically for every reason to prescribe warfarin.
Mechanical-valve INR targets vary by valve position, model and thromboembolic risk: the 2020 ACC/AHA guideline uses 2.5 for a current-generation bileaflet mechanical aortic valve without additional risk factors and 3.0 for a mechanical mitral valve. [10][14]
For INR 4.5 to 10 without clinically relevant bleeding, temporarily holding warfarin is usually favored over routine vitamin K, with individualized follow-up and risk assessment. Life-threatening VKA bleeding instead requires stopping the drug and rapid reversal with four-factor PCC plus IV vitamin K; plasma is an alternative when PCC is unavailable. Vitamin K alone acts too slowly for immediate factor replacement. [10]
UFH enhances antithrombin-mediated inhibition of IIa and Xa and is commonly monitored using aPTT or anti-Xa according to the setting. LMWH has relatively greater anti-Xa action; routine aPTT is not its monitoring test, and routine anti-Xa measurement is unnecessary in many patients. Protamine reverses UFH and only partially reverses LMWH. Dabigatran directly inhibits thrombin; idarucizumab specifically reverses it when emergency reversal is indicated. Apixaban and rivaroxaban inhibit Xa. Normal PT/aPTT cannot reliably exclude clinically significant DOAC effect; timing, kidney function and suitable drug-calibrated assays matter. [1][10][12]
Current U.S. availability changes a familiar reversal answer: AstraZeneca ended U.S. Andexxa sales on December 22, 2025 after FDA identified serious safety concerns. Do not carry forward an automatic andexanet recommendation for a U.S. emergency. Stop the Xa inhibitor, control the bleeding source and use current institutional specialist-guided reversal protocols, which may include four-factor PCC. Regulatory status and options differ by jurisdiction. [11][10]
Try it here · Checkpoint 3 of 3
Make your prediction before reading the choices. A first attempt is just a starting point.
Case 32
Show answer and explanations for case 32
A. 2.5 for the aortic valve; 3.0 for the mitral valve (Best answer)
The guideline distinguishes current-generation low-risk mechanical aortic valves from mechanical mitral valves.
B. 3.0 for the aortic valve; 2.5 for the mitral valve (Why this does not fit)
This reverses the usual targets for the stated valve positions and risk profiles.
C. 2.5 for both valves (Why this does not fit)
This overlooks the higher target recommended for a mechanical mitral valve.
D. 3.0 for both valves (Why this does not fit)
An aortic target of 3.0 applies to additional risk factors or older-generation prostheses, which the stem excludes.
Takeaway: Preserve valve-specific anticoagulation distinctions instead of one universal range.
A. Replace consumed factors and postpone antibiotics until coagulation normalizes (Why this does not fit)
Delaying control of sepsis leaves the driver of consumption active; resuscitation and infection treatment proceed urgently.
B. Use therapeutic anticoagulation as the sole initial hemostatic intervention (Why this does not fit)
Anticoagulation may be considered in selected thrombosis-predominant DIC, but this bleeding septic patient also needs trigger control and appropriate support.
C. Treat as immune TTP with plasma exchange as the principal intervention (Why this does not fit)
TTP is a differential for thrombocytopenia and hemolysis, but sepsis with factor consumption and oozing supports DIC.
D. Treat infection and shock; guide blood components by bleeding and clinical need (Best answer)
DIC requires control of the trigger while supporting hemostasis where clinically necessary.
Takeaway: Treat the cause of consumption as well as its immediate consequences.
